Big News!
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation of its second clinical candidate, Samcyprone™, for the treatment of Malignant Melanoma Stage